sb 203580 has been researched along with valerates in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (valerates) | Trials (valerates) | Recent Studies (post-2010) (valerates) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 2,251 | 294 | 457 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eley, HL; Russell, ST; Tisdale, MJ | 1 |
1 other study(ies) available for sb 203580 and valerates
| Article | Year |
|---|---|
Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-alpha and angiotensin II by beta-hydroxy-beta-methylbutyrate.
Topics: Angiotensin II; Animals; Caspase 3; Caspase 8; Cells, Cultured; Down-Regulation; Drug Evaluation, Preclinical; Enzyme Inhibitors; Imidazoles; Interferon-gamma; Metabolic Networks and Pathways; Mice; Models, Biological; Muscle Fibers, Skeletal; Muscle Proteins; Muscular Atrophy; p38 Mitogen-Activated Protein Kinases; Phenylalanine; Protein Processing, Post-Translational; Pyridines; Reactive Oxygen Species; Tumor Necrosis Factor-alpha; Valerates | 2008 |